Oxford, United Kingdom
OxVax is a biotechnology startup developing a next generation cancer vaccine with a focus on solid tumor cancers. Founded in 2021 as a spin-out from the University of Oxford, the company is based in the United Kingdom. The technology is based on intellectual property from the Fairchild laboratory at the Sir William Dunn School of Pathology and exploits induced pluripotent stem cells (iPSC) as a novel source of CD141+ dendritic cells (DC). This proprietary subset holds unique properties that make them attractive candidates for cancer immunotherapy.
The most recent milestone for OxVax was securing a Seed Round investment on 21 April 2021. The investors in this round included Evotec and Lead Compass Investment.
Keep in mind that it is important to keep a close eye on the development of OxVax as their innovative approach to cancer treatment could hold significant potential in the biotechnology industry.
-logo.jpg "Denvax"){kind=logo}